Regorafenib and Nifuroxazide exert enhanced suppression of hepatocellular carcinoma by inhibiting STAT3 and immune remodeling

Oncology Reports 2026 Open access

Read full text
Authors: Kun Li, Jinwei Chen, Zhi Ping Zheng, Yichun Gao, Jiayu Zhang, Wenya Ding, Tongguo Yang, Yuyang Gu, Xuhua Duan, Tiesuo Zhao, Huijie Jia, Pengfei Chen
+1 more Jianzhuang Ren
DOI: 10.3892/or.2026.9074
Cited by: 1
References: 53

Abstract

, H22 tumor‑bearing mice treated with the combination exhibited suppressed tumor growth without systemic toxicity, along with changes in apoptotic proteins, enhanced tumor‑infiltrating immune cells and improved systemic immune responses. These findings indicated that the combination exerts enhanced suppression of HCC by inhibiting STAT3 and remodeling anti‑tumor immunity, providing preclinical evidence for a safe and effective strategy.

Fields of Study & Subjects

Cytokine Signaling Pathways and Interactions Hepatocellular Carcinoma Treatment and Prognosis Cancer Mechanisms and Therapy

Publication details

Journal / source
Oncology Reports
Publisher
Spandidos Publications
Volume
55
Issue
4
Pages
1–14
Publication date
11 February 2026
Language
EN